In recent decades, cancer immunotherapy, which harnesses the power of the host's immune system to eliminate cancer cells, has marked a significant advancement in cancer treatment. This approach offers a more precise and personalized therapeutic option compared to traditional chemotherapy and targeted therapies.
However, emerging evidence indicates that the metabolic dysregulation within cancer cells creates physiological conditions in tumors that suppress anti-tumor immunity by reprogramming the tumor microenvironment (TME) to be more immunosuppressive. This challenge hampers the effectiveness of cancer immunotherapy, highlighting the importance of targeting immunometabolism—ushering in a new chapter for cancer treatment.
Metabolism is a core process underlying essentially all biological functions. The integration of metabolism with immunity, known as immunometabolism, is at the forefront of immunology research, as it continues to transform the field.
Given its novelty and potential in cancer immunotherapy, immunometabolism is garnering increasing attention from the global medical and biotechnological industries. According to Raven Lin, co-founder and CEO of Pilatus Biosciences, cancer cells predominantly consume essential nutrients and produce harmful metabolic waste, thereby altering immune responses within the TME.
By dissecting immunometabolism, we can understand how the interplay between immunology and metabolism impacts the functions of T cells and other immune cells. This understanding can lead to the development of innovative treatments aimed at reprogramming the TME and enhancing the effectiveness of immunotherapy.
Pilatus Biosciences is advancing preclinical studies and translational medical research in the field of immunometabolism at globally renowned research institutions and medical centers. The company has also developed multiple pipelines aimed at creating innovative treatments that target immunometabolism.
Unveiling outstanding PLT012 preclinical results
Founded by Prof. Ping-Chih Ho and Dr. Raven Lin at the Ludwig Cancer Research (Lausanne), Pilatus Biosciences pioneers the development of first-in-class biologics targeting metabolic checkpoints. These cutting-edge innovations aim to advance cancer immunotherapy and tackle the current challenges in cancer treatment. The Pilatus Biosciences team boasts extensive knowledge and experience in immunology, oncology, and biotechnology, providing a solid foundation for its biologics research and development. Continuing to push the frontiers of cancer medicine, Pilatus Biosciences is committed to delivering more effective and safer treatment options to conquer cancer's greatest challenges.
Pilatus Biosciences' first groundbreaking antibody, PLT012, was developed to block CD36-mediated fatty acid uptake, driving immunometabolic reprogramming in the TME. This leads to remarkable anti-tumor efficacy and inhibits the growth and spread of cancer cells. Pilatus Biosciences has presented preclinical proof-of-concept data of PLT012, particularly in the context of liver and colon cancer, at several international medical conferences.
As a leading research group in immunometabolism, Prof. Ping-Chih Ho, co-founder of Pilatus Biosciences, focuses on studying how immune cells' metabolic adaptations are regulated or modulated in response to the tumor microenvironment. Prof. Ho's in-depth research on T cell metabolism in the tumor microenvironment has laid a solid foundation for Pilatus Biosciences' development of innovative immunotherapy and played a critical role in Pilatus Biosciences' remarkable achievements.
Three major bottlenecks in today's immunotherapy are: (1) exhaustion and dysfunction of anti-tumor immune cells, (2) immunosuppression within the tumor microenvironment, and (3) the challenge of selectively activating anti-tumor immune cells without affecting systemic immunity in the body. Pilatus Biosciences' PLT012 addresses these issues by blocking CD36-mediated fatty acid uptake. This immunometabolic mechanism selectively activates anti-tumor immune cells and reduces immunosuppression, effectively overcoming the current limitations of immunotherapy. Credit: Pilatus Biosciences
Pilatus Biosciences establishes a Subsidiary in Taiwan to strengthen R&D and fundraising efforts
Leveraging its strong expertise in immunometabolism research, Pilatus Biosciences further works with a renowned European cancer center to establish an ex-vivo patient sample culture platform. This platform retains the tumor microenvironment and cell populations of patients' cancer tissues, enabling efficacy assessment across various cancers.
As part of its strategy to enhance R&D capabilities, Pilatus Biosciences plans to build a lab in Taiwan starting in July 2024. Pilatus Biosciences' endeavors not only provide more precise data for personalized medical care but also facilitate the selection of indications and biomarkers during biologics development. This approach can significantly reduce the risks of biologics development while greatly benefiting the advances of personalized medical care.
According to Lin, Taiwan has cultivated a comprehensive industry ecosystem for pharmaceutical industry from translational research disease model, manufacturing, pre-clinical testing, and clinical development, gradually establishing itself as a global leader in this field. To accelerate its development, in 2023, Pilatus Biosciences partnered with Mosaic Venture Labs, a startup accelerator based in TTA.
This collaboration aims to leverage Mosaic Venture Labs' influence and resources in the Asia-Pacific region to drive the company's growth and advancement through every stage of R&D. Pilatus Biosciences is now collaborating with multiple Taiwan-based research institutions and aims to build a strong and agile operation team in Taiwan that will connect with the global research community.
Phase-one human clinical trials for PLT012 in Taiwan and the US are scheduled to begin in early 2025. Mosaic Venture Labs is assisting Pilatus Biosciences in a round of funding aimed at raising US$10 million. The startup accelerator's network of biotech venture capital partners in Taiwan will help Pilatus Biosciences build up a solid foundation for its subsequent development. Hopefully, all these efforts will enable Pilatus Biosciences to present more treatment options and opportunities for patients through its biologics development achievements.
